## Welcome!

- Audio for this event is available via ReadyTalk<sup>®</sup> Internet Streaming.
- No telephone line is required.
- Computer speakers or headphones are necessary to listen to streaming audio.
- Limited dial-in lines are available.
   Please send a chat message if needed.
- This event is being recorded.




## **Troubleshooting Audio**


Audio from computer speakers breaking up?

Audio suddenly stop?

Click Refresh icon


or –
Click F5






## **Troubleshooting Echo**

- Hear a bad echo on the call?
- Echo is caused by multiple browsers/tabs open to a single event (multiple audio feeds.)
- Close all but one browser/tab and the echo will clear up.



**Example of Two Browsers Tabs open in Same Event** 

## **Submitting Questions**





# PCHQR Program: 2018 Updates to Measures

#### Lisa Vinson, BS, BSN, RN

Program Lead

PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

Hospital Inpatient Value, Incentives, and Quality Reporting (VIQR)

Outreach and Education Support Contractor (SC)

**February 22, 2018** 

## **Acronyms and Abbreviations**

ASTRO ADT AHRQ AJCC CAUTI	American Society for Radiation Oncology Androgen Deprivation Therapy Agency for Healthcare Research and Quality American Joint Committee on Cancer Catheter-Associated Urinary Tract Infections Centers for Disease Control and Prevention	ICD-10-CM ICU MRSA NHSN NQF OCM	International Classification of Diseases, Tenth Revision, Clinical Modification Intensive Care Unit Methicillin-Resistant Staphylococcus aureus National Healthcare Safety Network National Quality Forum Oncology Care Measure
CDI	Clostridium difficile Infection	OQR	Outpatient Quality Reporting
CE	Continuing Education	PCH	PPS-Exempt Cancer Hospital
CLABSI	Central Line-Associated Bloodstream	<b>PCHQR</b>	PPS-Exempt Cancer Hospital Quality Reporting
	Infection	PLND	Pelvic Lymph Node Dissection
CMS	Centers for Medicare & Medicaid Services	POS	Place of Service
CPT	Current Procedural Terminology	PPS	Prospective Payment System
CST	Cancer-Specific Treatment	PQRS	Physician Quality Reporting System
CY	Calendar Year	PSA	Prostate Specific Antigen
EBRT	External Beam Radiotherapy	Q	Quarter
ECE	Extraordinary Circumstances Exception	QPP	Quality Payment Program
ED	Emergency Department	SBRT	stereotactic body radiation therapy
EOL	End-of-Life	SC	Support Contractor
FY	Fiscal Year	SRS	Stereotactic Radiosurgery
HAI	Healthcare-Associated Infection	SSI	Surgical Site Infection
HCAHPS	Hospital Consumer Assessment of Healthcare Providers and Systems	VIQR	Value, Incentives, and Quality Reporting

02/22/2018

**HCP** 

Healthcare Personnel

## **Purpose**

This presentation will provide participants in the PCHQR Program an overview of the changes in the measure specifications effective for CY 2018.

## **Objectives**

Upon completion of this event, participants will be able to:

- Locate the source documentation for the significant specification changes.
- Apply the updated specifications to accurately abstract the measures for CY 2018.

02/22/2018 8

## Safety and HAI Measures for the FY 2020 Program Year and Subsequent Years

### Safety and HAI

Short Name	NQF#	Measure Name
CLABSI	0139	NHSN Central line-associated Bloodstream Infection Outcome Measure
CAUTI	0138	NHSN Catheter-associated Urinary Tract Infection Outcome Measure
SSI	0753	ACS-CDC Harmonized Procedure Specific SSI Outcome Measure (currently includes SSIs following colon surgery and abdominal hysterectomy surgery)
CDI	1717	NHSN Facility-wide Inpatient Hospital-onset CDI Outcome Measure
MRSA	1716	NHSN Facility-wide Inpatient Hospital-onset MRSA Bacteremia Outcome Measure
HCP	0431	Influenza Vaccination Coverage Among HCP

# Clinical Process/OCMs and Intermediate Clinical Outcome Measures for FY 2020 Program Year and Subsequent Years

Clinical Process/OCMs				
Short Name	nort Name NQF# Measure Name			
N/A	0382	Oncology: Radiation Dose Limits to Normal Tissues		
N/A	0383	Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology		
N/A	0384	Oncology: Medical and Radiation – Pain Intensity Quantified		
N/A	0390	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients		
N/A	0389	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients		
EOL-Chemo	0210	Proportion of Patients Who Died From Cancer Receiving Chemotherapy in the Last 14 Days of Life*		
EOL-Hospice	0215	Proportion of Patients Who Died from Cancer Not Admitted to Hospice*		
Intermediate Clinical Outcome Measures				
Short Name	Short Name NQF# Measure Name			

# Short Name NQF # Measure Name EOL-ICU 0213 Proportion of Patients Who Died From Cancer Admitted to the ICU in the Last 30 Days of Life\* EOL-3DH 0216 Proportion of Patients Who Died From Cancer Admitted to Hospice for Less than Three Days\*

<sup>\*</sup>This measure is finalized for adoption for the FY 2020 program year in section IX.B.4.b of the preamble of this final rule.

### Patient Engagement/Experience of Care, Clinical Effectiveness, and Claims-Based Outcome Measures for FY 2020 Program Year and Subsequent Years

Patient Engagement/Experience of Care				
Short Name NQF # Measure Name				
HCAHPS	0166	Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey		

Clinical Effectiveness Measure			
Short Name NQF # Measure Name			
EBRT	1822	External Beam Radiotherapy for Bone Metastases	


Claims-Based Outcome Measure				
Short Name	Short Name NQF # Measure Name			
N/A	N/A	Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy		

PCHQR Program: 2018 Updates to Measures

### **Quality Payment Program**

# Where to Find the Clinical Process/OCM and Intermediate Clinical Outcome Measures Specifications

The PQRS measures are listed on the CMS Quality Payment Program website at <a href="https://qpp.cms.gov/">https://qpp.cms.gov/</a>.



## Where are the Specifications?

Scroll to the bottom of the QPP home page.





## **QPP Resource Library**

# Quality Payment

About > Resource Library


# Resource Library

To make it easier for you to search and find what you're looking for by topic, year, or title, we've moved the Resource Library to CMS.gov.

To get notified when there are new QPP resources, subscribe to email updates.

Direct link: <a href="https://qpp.cms.gov/about/resource-library">https://qpp.cms.gov/about/resource-library</a>

## 2018 QPP Resources



02/22/2018 16

## **QPP – PCH Measure Crosswalk**

Name	NQF Measure #	PCH Measure #	QPP Quality ID #
Radiation Dose Limits to Normal Tissues	0382	PCH-14	156
Plan of Care for Pain	0383	PCH-15	144
Pain Intensity Quantified	0384	PCH-16	143
Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer	0389	PCH-18	102
Combination Androgen Deprivation Therapy for High or Very High Risk Prostate Cancer	0390	PCH-17	104

## **QPP – PCH Measure Crosswalk**

(continued)

Name	NQF Measure #	PCH Measure #	QPP Quality ID #	
Proportion of Patients Who Died From Cancer Receiving Chemotherapy in the Last 14 Days of Life	0210	PCH-32	453	
Proportion of Patients Who Died From Cancer Admitted to the ICU in the Last 30 Days of Life	rom Cancer ed to the ICU in the		455	
Proportion of Patients Who Died From Cancer Not 0215 Admitted to Hospice		PCH-34	456	
Proportion of Patients Who Died From Cancer Admitted to Hospice for Less Than Three Days	0216	PCH-35	457	

## **Quality Measure Specifications**

- Quality
  - Quality Measure Specifications: 12/27/2017
    - Claims Registry Measures 001-050
    - Claims Registry Measures 051-100
    - Claims Registry Measures 101-150
    - Claims Registry Measures 151-200
    - Claims Registry Measures 201-250
    - Claims Registry Measures 251-300
    - Claims Registry Measures 301-350
    - Claims Registry Measures 351-400
    - Claims Registry Measures 401-467

Select here for EOL measures specifications

Web Interface Measures & supporting documents 12/27/2017

# Locating and Opening the Claim-Registry File

Name	Туре	Compressed size	Password Siz	'e	Ratio	Date modified
Claims-Registry-Measures-101-150	File folder					
			500000	201-0-10 P++		24.66.43.11.21.2
2018_Measure_102_Registry		crobat Document	363			396 KB
2018_Measure_104_Registry		robat Document	398	100 m		436 KB
2018_Measure_109_Claims		robat Document	263			291 KB
2018_Measure_109_Registry	Adobe Ad	robat Document	264	KB No		292 KB
2018_Measure_110_Claims	Adobe Ad	robat Document	322 1	(B No		353 KB
2018_Measure_110_Registry	Adobe A	crobat Document	3111	(B No		341 KB
2018_Measure_111_Claims	Adobe Ad	robat Document	320 1	KB No		350 KB
2018_Measure_111_Registry	Adobe Ad	robat Document	3161	KB No		345 KB
2018_Measure_112_Claims	Adobe Ad	robat Document	363	KB No		408 KB
2018_Measure_112_Registry	Adobe Ad	robat Document	441	KB No		480 KB
2018_Measure_113_Claims	Adobe Ad	robat Document	218	KB No		246 KB
2018_Measure_113_Registry	Adobe Ad	robat Document	240	KB No		267 KB
2018_Measure_116_Registry	Adobe Ad	robat Document	2341	KB No		270 KB
2018_Measure_117_Claims	Adobe Ad	robat Document	322 1	KB No		360 KB
2018_Measure_117_Registry	Adobe Ad	robat Document	242 1	KB No		270 KB
2018_Measure_118_Registry	Adobe Ad	robat Document	370 1	KB No		425 KB
2018_Measure_119_Registry	Adobe Ad	robat Document	228	KB No		262 KB
2018_Measure_122_Registry	Adobe Ad	robat Document	311	KB No		345 KB
2018_Measure_126_Registry	Adobe Ad	robat Document	213	KB No		243 KB
2018 Measure 127 Registry	Adobe Ad	robat Document	203	KB No		227 KB
2018 Measure 128 Claims	Adobe Ad	robat Document	284	KB No		327 KB

02/22/2018

280 KB No

Adobe Acrobat Document

322 KB

2018 Measure 128 Registry

PCHQR Program: 2018 Updates to Measures

#### **2018 Quality Payment Program Measure Specifications**

- What remains the same?
  - Expanded diagnosis cohort which includes patients with a diagnosis of pancreatic, lung breast or rectal cancer

#### **AND**

- Receiving 3D conformal radiation therapy
- Excludes patients with metastatic cancer
- What is new?
  - No significant changes

02/22/2018 22

- What remains the same?
  - Includes patients with a diagnosis of cancer

#### **AND**

- Currently receiving chemotherapy OR
- Radiation therapy
- Report having pain with a documented plan of care to address it
- What is new?
  - Denominator changes
    - Updated denominator criteria telehealth modifiers to include 95 and POS 02
    - Updated denominator coding
      - Deleted ICD-10-CM: C93.2, D47.0
      - Added ICD-10-CM: C49.4, C96.20, C96.21, C96.22, C96.29, D49.5

- Deleted CPT: 77470

- What remains the same?
  - Includes patients with a diagnosis of cancer

#### **AND**

- Receiving chemotherapy OR
- Radiation therapy
- Pain intensity is quantified
- What is new?
  - Denominator changes
    - Updated denominator criteria telehealth modifiers to include 95 and POS 02
    - Updated denominator coding
      - Added ICD-10-CM: C49.4, C96.20, C96.21, C96.22, C96.29, D49.5
      - Deleted CPT code: 77470
  - Updated rationale and clinical recommendation statements

- What remains the same?
  - Includes patients with prostate cancer at low risk (or very low) of recurrence
  - Includes patients receiving interstitial prostate brachytherapy, OR EBRT to prostate, OR radical prostatectomy, OR cryotherapy to prostate
  - Denominator includes patients with a diagnosis of prostate cancer at low (or very low) risk of recurrence

# 2018 QPP Measure Specifications – NQF #0389 (continued)

- What is new?
  - Updated denominator definitions
    - Very low risk: PSA density changed from < 0.15 ng/mL/cm3 to < 0.15 ng/mL/cm3</li>
    - Low risk: Gleason score changed from 6 or less to 6
  - Added Numerator Note: Denominator exception(s) are determined any time after diagnosis of prostate cancer
  - Updated rationale and clinical recommendation statements

- What remains the same?
  - Includes patients with prostate cancer at high or very high risk of recurrence receiving EBRT to the prostate (prescribed androgen deprivation therapy in combination with EBRT to the prostate)
  - Measure codes
  - Patients with multiple adverse factors may be shifted to an elevated risk category
    - Intermediate risk to high risk
    - High risk to very high risk

# 2018 QPP Measure Specifications – NQF #0390 (continued)

- What is new?
  - Updated Title and Description
    - Replaced adjuvant hormonal therapy with combination androgen deprivation therapy or androgen deprivation therapy in combination with EBRT to the prostate
  - Updated Denominator Definitions
    - Gleason grade groups now included for all risk strata
    - Very low risk: PSA density changed from < 0.15 ng/mL/cm3 to < 0.15 ng/mL/cm3</li>
    - Low risk: Gleason score changed from 6 or less to 6

# 2018 QPP Measure Specifications – NQF #0390 (continued)

- Updated the numerator
  - Added Numerator Note: Denominator Exception(s) are determined on the date of the denominator eligible encounter.
  - Added numerator options
    - Performance Met (G9894)
    - Denominator Exception of Medical Reasons (G9895)
    - Denominator Exception of Patient Reasons (G9896)
    - Performance Not Met (G9897)
- Updated rationale and clinical recommendation statements

# Rationale and Clinical Recommendation Statements – NQF #0390

#### Rationale

- Research studies have shown with androgen deprivation therapy in combination with EBRT:
  - Patients can live longer and have lower risk of recurrence.
  - Cost-effectiveness and quality-adjusted life years increase.
  - Utilization rates have increased, but they still remain suboptimal.
- Clinical rationale statements updates
  - Recommended options for patients at very high risk:
    - Option for EBRT plus ADT and docetaxel has been removed.
    - Radical prostatectomy plus PLND is for younger, healthier patients with no tumor fixation to the pelvic side wall.
    - ADT or observation is for patients not candidates for definitive therapy.

- Who is included?
  - Patients who died from cancer receiving chemotherapy in the last 14 days of life
- What is new?
  - Updated denominator coding
    - Deleted ICD-10-CM: C96.2
    - Added ICD-10-CM: C96.20, C96.21, C96.22, C96.29

- Who is included?
  - Patients who died from cancer not admitted to hospice
- What is new?
  - Updated denominator coding
    - Deleted ICD-10-CM: C96.2
    - Added ICD-10-CM: C96.20, C96.21,
       C96.22, C96.29

- Who is included?
  - Patients who died from cancer admitted to the ICU in the last 30 days of life
- What is new?
  - Updated denominator coding
    - Deleted ICD-10-CM: C96.2
    - Added ICD-10-CM: C96.20, C96.21, C96.22, C96.29

- Who is included?
  - Patients who died from cancer, were admitted to hospice, and spent less than three days there
- What is new?
  - Updated denominator coding
    - Deleted ICD-10-CM: C96.2
    - Added ICD-10-CM: C96.20, C96.21, C96.22, C96.29

02/22/2018 34

PCHQR Program: 2018 Updates to Measures

### Other PCHQR Program Measure Information

## **EBRT – NQF #1822**

- New <u>measure specifications</u> currently under consideration by NQF
- On-going collaboration with:
  - o CMS
  - Hospital Outpatient Quality Reporting (OQR) Program SC
  - American Society for Radiation
     Oncology (ASTRO)

## **PCHQR Program Measures**

- CST measures (NQF #0223, #0559, #0220)
  - o Finalized for removal in the FY 2018 final rule publication.
  - No data collection required for diagnoses effective for January 1, 2018.
- HAI measures (NQF #0139, #0138, #0753, #1717, #1716, #0431)
  - Currently no changes.
- HCAHPS Survey Data (NQF #0166)
  - New pain questions effective for discharges January 1, 2018, and forward.
  - For more information, visit <u>HCAHPS home page</u> and <u>technical</u> <u>specifications page</u>.
- Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure
  - Chemotherapy Dry Run Summary Report available on QualityNet Chemotherapy Measure Dry Run Resources page.

PCHQR Program: 2018 Update to Measures

### **Key Dates and Reminders**

# Updated NHSN Agreement to Participate and Consent

- The updated NHSN agreement is for all current NHSN users who enrolled in NHSN <u>prior</u> to December 2, 2017.
  - Includes primary contacts and facility administrators
- As of January 30, 2018, the updated consent is available for review and electronic signature.
  - Must be completed by <u>April 14, 2018</u>
- If you have questions, email <a href="NHSN@cdc.gov">NHSN@cdc.gov</a> with subject line "NHSN Re-consent."
- Refer to the <u>Winter 2018 Quality Reporting</u> Center Newsletter.

# Upcoming PCHQR Program Event and Deadlines

#### March 22, 2018

- PCHQR Program: Updates to Measure Information Forms (MIFs), Algorithms, and Paper Tools
- April 4, 2018
  - 4Q 2017 HCAHPS Survey Data
- May 15, 2018
  - 3Q 2017 CST colon and breast data
  - 1Q 2017 CST hormone data
  - 4Q 2017 HAI data
  - 4Q 2017 1Q 2018 Influenza Vaccination
     Coverage Among HCP data\*

<sup>\*</sup>Note: HCP measure data falls under the CMS-granted hurricane-related ECE.

# Hospital Compare Key Dates

#### April 2018 contains:


- 1Q 2016 through 4Q 2016 chemo data
- 3Q 2015 through 2Q 2016 hormone data
- 3Q 2016 through 2Q 2017 HCAHPS Survey data
  - Preview period is February 1 through March 2, 2018.
  - Hospital Compare tentative release is April 25, 2018.

#### July 2018 contains:

- 2Q 2016 through 1Q 2017 chemo data
- 4Q 2015 through 3Q 2016 hormone data
- 4Q 2016 through 3Q 2017 HCAHPS Survey data
  - Preview period is tentatively scheduled for May 4 through June 2, 2018.
  - Hospital Compare tentative release is July 25, 2018.

# Accessing the *QualityNet* **Questions and Answers Tool**

#### **QualityNet Questions and Answers Tool**



# **Continuing Education Approval**

This program has been pre-approved for 1.0 continuing education (CE) unit for the following professional boards:

#### National

Board of Registered Nursing (Provider #16578)

#### Florida

- Board of Clinical Social Work, Marriage & Family Therapy and Mental Health Counseling
- Board of Nursing Home Administrators
- Board of Dietetics and Nutrition Practice Council
- Board of Pharmacy

**Please Note:** To verify CE approval for any other state, license, or certification, please check with your licensing or certification board.

## **CE Credit Process**

- Complete the ReadyTalk® survey that will pop up after the webinar, or wait for the survey that will be sent to all registrants within the next 48 hours.
- After completion of the survey, click "Done" at the bottom of the screen.
- Another page will open that asks you to register in the HSAG Learning Management Center.
  - This is a separate registration from ReadyTalk<sup>®</sup>.
  - Please use your personal email so you can receive your certificate.


Healthcare facilities have firewalls up that block our certificates.

## **CE Certificate Problems**


- If you do not immediately receive a response to the email that you signed up with in the Learning Management Center, you have a firewall up that is blocking the link that was sent.
- Please go back to the New User link and register your personal email account.
  - Personal emails do not have firewalls.

<sup>\*</sup>Please download your continuing education certificate for your records. HSAG retains attendance records for four years, not certificates.


# **CE Credit Process: Survey**




## **CE Credit Process: Certificate**



## **CE Credit Process: New User**



# **CE Credit Process: Existing User**



PCHQR Program: 2017 Update to Measures

### **Closing Remarks**

## **Disclaimer**

This presentation was current at the time of publication and/or upload onto *Quality Reporting Center* and *QualityNet* websites. Medicare policy changes frequently. Any links to Medicare online source documents are for reference use only. In the case that Medicare policy, requirements, or guidance related to this presentation change following the date of posting, this presentation will not necessarily reflect those changes; given that it will remain as an archived copy, it will not be updated.

This presentation was prepared as a service to the public and is not intended to grant rights or impose obligations. Any references or links to statutes, regulations, and/or other policy materials included in the presentation are provided as summary information. No material contained therein is intended to take the place of either written laws or regulations. In the event of any conflict between the information provided by the presentation and any information included in any Medicare rules and/or regulations, the rules and regulations shall govern. The specific statutes, regulations, and other interpretive materials should be reviewed independently for a full and accurate statement of their contents.